Does Co-enzyme Q10 supplementation in patients with depression improve their symptoms
- Conditions
- Health Condition 1: F30-F39- Mood [affective] disorders
- Registration Number
- CTRI/2023/04/051582
- Lead Sponsor
- AIIMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. All adult patients of either sex aged 18-65 years with clinical diagnosis of Major Depressive Disorder as per DSM-5 criteria.
2. Patients on stable dose (no change in dose) of anti-depressants for 4 weeks.
3. Patients willing to participate and give consent.
1. Patients with comorbid psychiatric or neurological disorders such as anxiety disorder, schizophrenia, current state of psychosis, epilepsy and substance use disorder
2. Patient currently having suicidal ideas or history of suicidal plan/attempt.
ï?§ Pregnancy or lactation or expecting to get pregnant during the treatment.
ï?§ Patient on concomitant warfarin therapy, anti-hypertensive drugs or statins.
ï?§ Patients with chronic liver disease.
ï?§ Poor adherence to medications.
ï?§ Patient not willing to give consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ï?§ To evaluate the effect of add on COQ10 on depressive symptoms as assessed by MADRS in patients with Major depressive disorder after 4 weeks of therapy.Timepoint: ï?§ To evaluate the effect of add on COQ10 on depressive symptoms as assessed by MADRS in patients with Major depressive disorder after 4 weeks of therapy.
- Secondary Outcome Measures
Name Time Method 1. To evaluate the change in serum IDO and serum BDNF after 4 weeks of add on CoQ10 therapy. <br/ ><br>2. To evaluate the change in cognition score after 4 weeks of add-on CoQ10 therapy. <br/ ><br>3. To evaluate the safety of add on COQ10. <br/ ><br>Timepoint: At baseline and 4 weeks